Tag: Crohn’s Disease
Upadacitinib Superior to Placebo in Moderate-to-Severe Crohn Disease
Superior response seen with upadacitinib induction and maintenance treatments
FDA Approves First Pill to Treat Moderate-to-Severe Crohn Disease
In clinical trials, more patients taking Rinvoq achieved remission and reduced intestinal inflammation compared with patients given a placebo
Small Increase in Lymphoma Risk Seen With Crohn Disease, Ulcerative Colitis
Hazard ratios highest for patients exposed to immunomodulators and biologics or second-line biologics
Adalimumab + Methotrexate Beneficial for Pediatric Crohn Disease
Reduction in treatment failure seen for adalimumab, but not infliximab, initiators treated with methotrexate combination therapy
Genetic, Lifestyle Factors Independently Linked to IBD Risk
For those with high genetic risk, hazard ratios were reduced nearly by half for favorable lifestyle versus unfavorable lifestyle
Perianal Disease, Stricturing or Penetrating Behavior Tied to Crohn Disease Outcomes
Findings in Brazil similar to those in countries with a high prevalence of Crohn disease
Lifestyle Modification Can Reduce Proportion of IBD Burden
A considerable proportion of ulcerative colitis, Crohn disease cases could be prevented by adherence to low modifiable risk score, healthy lifestyle
About Half of Patients With IBD Have Zinc Deficiency
Overall mean zinc deficiency prevalence 54 percent in Crohn disease and 41 percent in ulcerative colitis
C-Section Linked to Increased Risk for Crohn Disease in Offspring
No association seen between mode of delivery and other gastrointestinal disorders later in life among offspring
Diagnostic Accuracy of MRE Indices Studied for Active Crohn Disease
High sensitivity, but low specificity, seen for sMARIA, London, 'extended' London scores for active terminal ileal Crohn disease
